Krebs von den Lungen-6 glycoprotein circulating levels are not useful as prognostic marker in COVID-19 pneumonia: A large prospective cohort study.
COVID-19
Krebs von den Lungen-6 (KL-6)
biomarker
pneumonia
predictor
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
06
2022
accepted:
19
07
2022
entrez:
25
8
2022
pubmed:
26
8
2022
medline:
26
8
2022
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) has rapidly expanded worldwide. Currently, there are no biomarkers to predict respiratory worsening in patients with mild to moderate COVID-19 pneumonia. Small studies explored the use of Krebs von de Lungen-6 circulating serum levels (sKL-6) as a prognostic biomarker of the worsening of COVID-19 pneumonia. We aimed at a large study to determine the prognostic value of sKL-6 in predicting evolving trends in COVID-19. We prospectively analyzed the characteristics of 836 patients with COVID-19 with mild lung disease on admission. sKL-6 was obtained in all patients at least at baseline and compared among patients with or without respiratory worsening. The receiver operating characteristic curve was used to find the optimal cutoff level. A total of 159 (19%) patients developed respiratory worsening during hospitalization. Baseline sKL-6 levels were not higher in patients who had respiratory worsening (median {IQR} 315.5 {209-469} vs. 306 {214-423} U/ml
Identifiants
pubmed: 36004366
doi: 10.3389/fmed.2022.973918
pmc: PMC9393380
doi:
Types de publication
Journal Article
Langues
eng
Pagination
973918Informations de copyright
Copyright © 2022 Castellví, Castillo, Corominas, Mariscal, Orozco, Benito, Pomar, Baucells, Mur, de la Rosa-Carrillo, Lobo, Millan, Hernández de Sosa, Filella, Matas, Martínez-Martínez, Juarez, Casademont and Domingo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
ERJ Open Res. 2017 Aug 30;3(3):
pubmed: 28875146
Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1680-4
pubmed: 9817725
Int J Environ Res Public Health. 2021 Feb 20;18(4):
pubmed: 33672761
Respirology. 2006 Mar;11(2):164-8
pubmed: 16548901
Cytokine. 2021 Dec;148:155513
pubmed: 34507246
J Med Virol. 2021 Jan;93(1):158-160
pubmed: 32633842
Exp Hematol Oncol. 2020 Jul 17;9:16
pubmed: 32695551
Chest. 2016 Aug;150(2):307-13
pubmed: 26836924
EBioMedicine. 2020 Aug;58:102887
pubmed: 32736307
J Intensive Care. 2020 Jul 10;8:49
pubmed: 32665858
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Virology. 2022 Jan;566:106-113
pubmed: 34896901
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
J Med Virol. 2020 Oct;92(10):1875-1883
pubmed: 32441789
J Pers Med. 2021 Oct 25;11(11):
pubmed: 34834437
J Rheumatol. 2016 Oct;43(10):1825-1831
pubmed: 27481907
N Engl J Med. 2020 Sep 3;383(10):994
pubmed: 32649078
Biosci Trends. 2020 Sep 21;14(4):290-296
pubmed: 32565512
Semin Arthritis Rheum. 2020 Jun;50(3):480-491
pubmed: 32089354
BMJ. 2021 Apr 13;373:n967
pubmed: 33849936
Intensive Care Med. 2020 Jun;46(6):1099-1102
pubmed: 32291463
J Med Virol. 2020 Oct;92(10):2216-2220
pubmed: 32470148
BMC Pulm Med. 2020 Jan 8;20(1):6
pubmed: 31915006
Arch Bronconeumol (Engl Ed). 2020 Oct;56(10):676-677
pubmed: 32620418
Cytokine. 2021 May;141:155455
pubmed: 33548798
Eur Respir J. 2004 Jan;23(1):142-5
pubmed: 14738246
Am Rev Respir Dis. 1993 Sep;148(3):637-42
pubmed: 8368634
Int J Biol Sci. 2021 Apr 10;17(6):1565-1573
pubmed: 33907520
Dis Markers. 2016;2016:4759040
pubmed: 27293304
Crit Care Med. 2017 Aug;45(8):1317-1324
pubmed: 28538439
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
J Med Virol. 2021 Apr;93(4):2505-2512
pubmed: 33433006
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
BMC Bioinformatics. 2007 Jan 25;8:25
pubmed: 17254353
BMC Infect Dis. 2020 Jul 16;20(1):519
pubmed: 32677918
J Thorac Dis. 2017 Feb;9(2):362-371
pubmed: 28275485
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620937175
pubmed: 32615866
Clin Infect Dis. 2022 Aug 24;75(1):e849-e856
pubmed: 34893812
Rheumatology (Oxford). 2015 May;54(5):784-91
pubmed: 25288783
Arch Bronconeumol. 2021 Apr;57:34-41
pubmed: 34629641
Front Med (Lausanne). 2020 Aug 25;7:557
pubmed: 32984388
Respir Investig. 2021 Sep;59(5):596-601
pubmed: 33965361
Respir Investig. 2020 Nov;58(6):440-447
pubmed: 32863199
Respir Investig. 2012 Mar;50(1):3-13
pubmed: 22554854
PLoS One. 2020 Mar 12;15(3):e0229997
pubmed: 32163457
J Intensive Care. 2020 Apr 24;8:29
pubmed: 32341785